Loading data
CRVSNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development expense | 33.72 m USD | 19.39 m USD | 16.53 m USD | 24.47 m USD | 29.12 m USD |
| Operating profit | -42.97 m USD | -27.55 m USD | -23.41 m USD | -32.57 m USD | -38.63 m USD |
| Profit before tax | — | — | — | -41.31 m USD | -43.24 m USD |
| Income tax expense | 0 USD | — | 0 USD | 0 USD | 0 USD |
| Net income (reported basis) | -15.3 m USD | -62.3 m USD | -27 m USD | -41.3 m USD | -43.24 m USD |
| Net income attributable to common shareholders | -15.28 m USD | -62.29 m USD | -27.03 m USD | — | — |
| Basic earnings per share | -0.19 USD/share | -1.02 USD/share | -0.56 USD/share | -0.89 USD/share | -1.03 USD/share |
| Diluted earnings per share | -0.53 USD/share | -1.02 USD/share | -0.56 USD/share | -0.89 USD/share | -1.03 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.